Reuters logo
BRIEF-Amgen, Allergan to discuss data supporting biologics license application for ABP 215
2017年7月13日 / 中午12点24分 / 4 个月前

BRIEF-Amgen, Allergan to discuss data supporting biologics license application for ABP 215

July 13 (Reuters) - Allergan Plc

* Amgen and allergan to discuss data supporting biologics license application for abp 215, a biosimilar candidate to avastin® (bevacizumab)

* Amgen inc- ‍fda has set a biosimilar user fee act (bsufa) target action date of sept. 14, 2017, for abp 215​

* Amgen inc- ‍co, allergan will discuss data supporting abp 215 bla with oncologic drugs advisory committee of u.s. fda​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below